

Schultz Kare  
Form 3  
January 02, 2018

**FORM 3**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB  
Number: 3235-0104  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting  
Person \*

Â Schultz Kare

(Last) (First) (Middle)

C/O TEVA  
PHARMACEUTICAL  
INDUSTRIES LTD.,Â 5 BASEL  
STREET

(Street)

PETACH  
TIKVA,Â L3Â 4951033

(City) (State) (Zip)

2. Date of Event Requiring  
Statement

(Month/Day/Year)  
01/01/2018

3. Issuer Name **and** Ticker or Trading Symbol

TEVA PHARMACEUTICAL INDUSTRIES LTD  
[TEVA]

4. Relationship of Reporting  
Person(s) to Issuer

5. If Amendment, Date Original  
Filed(Month/Day/Year)

(Check all applicable)

\_\_\_\_ Director \_\_\_\_ 10% Owner  
\_\_X\_\_ Officer \_\_\_\_ Other  
(give title below) (specify below)  
President and CEO

6. Individual or Joint/Group  
Filing(Check Applicable Line)  
\_\_X\_\_ Form filed by One Reporting  
Person  
\_\_\_\_ Form filed by More than One  
Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security  
(Instr. 4)

2. Amount of Securities  
Beneficially Owned  
(Instr. 4)

3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)

4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form displays a  
currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security  
(Instr. 4)

2. Date Exercisable and  
Expiration Date  
(Month/Day/Year)

3. Title and Amount of  
Securities Underlying  
Derivative Security  
(Instr. 4)

4. Conversion  
or Exercise  
Price of  
Derivative

5. Ownership  
Form of  
Derivative  
Security:

6. Nature of Indirect  
Beneficial  
Ownership  
(Instr. 5)

## Edgar Filing: Schultz Kare - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Options (right to buy)	Â (1)	11/03/2027	Ordinary Shares (2)	591,719	\$ 11.4	D	Â
Restricted Share Units	Â (3)	Â (3)	Ordinary Shares (2)	540,002	\$ (4)	D	Â
Performance Share Units	Â (5)	Â (5)	Ordinary Shares (2)	649,914	\$ (5)	D	Â
Performance Share Units	Â (6)	Â (6)	Ordinary Shares (2)	751,504	\$ (6)	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Schultz Kare C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 5 BASEL STREET PETACH TIKVA,Â L3Â 4951033	Â	Â	Â President and CEO	Â

## Signatures

/s/ Dov Bergwerk, as attorney-in-fact for Kare Schultz 01/02/2018

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Stock options were granted on November 3, 2017, with 197,239 vesting on each of November 3, 2019 and November 1, 2020 and 197,241 vesting on November 1, 2021.
- (2) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- (3) Restricted share units were granted on November 3, 2017, with 63,613 vesting on November 3, 2019, 180,000 vesting on each of November 1, 2020 and November 1, 2021 and 116,389 vesting on November 1, 2022.
- (4) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- (5) Performance share units were granted on November 3, 2017 and represent a contingent right to receive, at settlement, ordinary shares at 0% to 300% of the reported target number of performance share units granted based on the percentage increase in the Issuer's share price during the six months ending on November 1, 2020 (based on the average closing trading price per share as reported on the New York Stock Exchange during such period), compared to the Issuer's share price on September 8, 2017, with 216,638 performance share units vesting on each of November 3, 2020, November 1, 2021 and November 1, 2022.
- (6) Performance share units were granted on November 3, 2017 and represent a contingent right to receive, at settlement, ordinary shares at 0% to 300% of the reported target number of performance share units granted based on the percentage increase in the Issuer's share price during the six months ending on November 1, 2022 (based on the average closing trading price per share as reported on the New York Stock Exchange during such period) compared to the Issuer's share price on September 8, 2017, vesting on November 1, 2022.

^

**Remarks:**

The Reporting Person is filing this form in connection with the Issuer's transition from a foreign p

**Exhibit List**

^ ^ ^ ^ ^ Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.